Breast carcinoma during pregnancy: International recommendations from an expert meeting

Sibylle Loibl, Gunter Von Minckwitz, Karin Gwyn, Paul Ellis, Jens U. Blohmer, Brigitte Schlegelberger, Monika Keller, Sebastian Harder, Richard L. Theriault, Diana Crivellari, Thomas Klingebiel, Frank Louwen, Manfred Kaufmann

Research output: Contribution to journalArticle

203 Citations (Scopus)

Abstract

BACKGROUND. Breast carcinoma during pregnancy (BCP) is a difficult clinical situation, as it appears to put the health of the mother in conflict with that of the fetus. METHODS. An international expert meeting was conducted to form guidelines on how to diagnose and treat women with BCP. RESULTS. The goal for treatment of the pregnant woman with breast carcinoma is the same as that of the nonpregnant breast carcinoma patient: local control of disease and prevention of systemic metastases. However, certain treatment modalities need to be modified because of the potential for adverse effects on the fetus. There is evidence to support the safety of anthracycline-based chemotherapy during the second and third trimesters of pregnancy (Oxford Level of Evidence [LOE] 2b). Because of the lack of evidence, the expert opinion was not to recommend the routine use of newer cytotoxic drugs like the taxanes during pregnancy (LOE 5). CONCLUSION. The recommendations provided should help to reach informed decision making by the patient. The ongoing prospective collection of data on BCP, such as that at the University of Texas M.D. Anderson Cancer Center (UTMDACC) and that of the German Breast Group/Breast International Group (GBG/BIG), is necessary to further our knowledge regarding the treatment of this unique group of breast carcinoma patients.

Original languageEnglish
Pages (from-to)237-246
Number of pages10
JournalCancer
Volume106
Issue number2
DOIs
Publication statusPublished - Jan 15 2006

Fingerprint

Breast Neoplasms
Pregnancy
Breast
Fetus
Taxoids
Anthracyclines
Expert Testimony
Third Pregnancy Trimester
Second Pregnancy Trimester
Pregnant Women
Decision Making
Therapeutics
Mothers
Guidelines
Neoplasm Metastasis
Safety
Drug Therapy
Health
Pharmaceutical Preparations
Neoplasms

Keywords

  • Breast carcinoma
  • Chemotherapy
  • Pregnancy
  • Recommendation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Loibl, S., Von Minckwitz, G., Gwyn, K., Ellis, P., Blohmer, J. U., Schlegelberger, B., ... Kaufmann, M. (2006). Breast carcinoma during pregnancy: International recommendations from an expert meeting. Cancer, 106(2), 237-246. https://doi.org/10.1002/cncr.21610

Breast carcinoma during pregnancy : International recommendations from an expert meeting. / Loibl, Sibylle; Von Minckwitz, Gunter; Gwyn, Karin; Ellis, Paul; Blohmer, Jens U.; Schlegelberger, Brigitte; Keller, Monika; Harder, Sebastian; Theriault, Richard L.; Crivellari, Diana; Klingebiel, Thomas; Louwen, Frank; Kaufmann, Manfred.

In: Cancer, Vol. 106, No. 2, 15.01.2006, p. 237-246.

Research output: Contribution to journalArticle

Loibl, S, Von Minckwitz, G, Gwyn, K, Ellis, P, Blohmer, JU, Schlegelberger, B, Keller, M, Harder, S, Theriault, RL, Crivellari, D, Klingebiel, T, Louwen, F & Kaufmann, M 2006, 'Breast carcinoma during pregnancy: International recommendations from an expert meeting', Cancer, vol. 106, no. 2, pp. 237-246. https://doi.org/10.1002/cncr.21610
Loibl S, Von Minckwitz G, Gwyn K, Ellis P, Blohmer JU, Schlegelberger B et al. Breast carcinoma during pregnancy: International recommendations from an expert meeting. Cancer. 2006 Jan 15;106(2):237-246. https://doi.org/10.1002/cncr.21610
Loibl, Sibylle ; Von Minckwitz, Gunter ; Gwyn, Karin ; Ellis, Paul ; Blohmer, Jens U. ; Schlegelberger, Brigitte ; Keller, Monika ; Harder, Sebastian ; Theriault, Richard L. ; Crivellari, Diana ; Klingebiel, Thomas ; Louwen, Frank ; Kaufmann, Manfred. / Breast carcinoma during pregnancy : International recommendations from an expert meeting. In: Cancer. 2006 ; Vol. 106, No. 2. pp. 237-246.
@article{42b77f4102d141918bf6c7bff86ce5d4,
title = "Breast carcinoma during pregnancy: International recommendations from an expert meeting",
abstract = "BACKGROUND. Breast carcinoma during pregnancy (BCP) is a difficult clinical situation, as it appears to put the health of the mother in conflict with that of the fetus. METHODS. An international expert meeting was conducted to form guidelines on how to diagnose and treat women with BCP. RESULTS. The goal for treatment of the pregnant woman with breast carcinoma is the same as that of the nonpregnant breast carcinoma patient: local control of disease and prevention of systemic metastases. However, certain treatment modalities need to be modified because of the potential for adverse effects on the fetus. There is evidence to support the safety of anthracycline-based chemotherapy during the second and third trimesters of pregnancy (Oxford Level of Evidence [LOE] 2b). Because of the lack of evidence, the expert opinion was not to recommend the routine use of newer cytotoxic drugs like the taxanes during pregnancy (LOE 5). CONCLUSION. The recommendations provided should help to reach informed decision making by the patient. The ongoing prospective collection of data on BCP, such as that at the University of Texas M.D. Anderson Cancer Center (UTMDACC) and that of the German Breast Group/Breast International Group (GBG/BIG), is necessary to further our knowledge regarding the treatment of this unique group of breast carcinoma patients.",
keywords = "Breast carcinoma, Chemotherapy, Pregnancy, Recommendation",
author = "Sibylle Loibl and {Von Minckwitz}, Gunter and Karin Gwyn and Paul Ellis and Blohmer, {Jens U.} and Brigitte Schlegelberger and Monika Keller and Sebastian Harder and Theriault, {Richard L.} and Diana Crivellari and Thomas Klingebiel and Frank Louwen and Manfred Kaufmann",
year = "2006",
month = "1",
day = "15",
doi = "10.1002/cncr.21610",
language = "English",
volume = "106",
pages = "237--246",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Breast carcinoma during pregnancy

T2 - International recommendations from an expert meeting

AU - Loibl, Sibylle

AU - Von Minckwitz, Gunter

AU - Gwyn, Karin

AU - Ellis, Paul

AU - Blohmer, Jens U.

AU - Schlegelberger, Brigitte

AU - Keller, Monika

AU - Harder, Sebastian

AU - Theriault, Richard L.

AU - Crivellari, Diana

AU - Klingebiel, Thomas

AU - Louwen, Frank

AU - Kaufmann, Manfred

PY - 2006/1/15

Y1 - 2006/1/15

N2 - BACKGROUND. Breast carcinoma during pregnancy (BCP) is a difficult clinical situation, as it appears to put the health of the mother in conflict with that of the fetus. METHODS. An international expert meeting was conducted to form guidelines on how to diagnose and treat women with BCP. RESULTS. The goal for treatment of the pregnant woman with breast carcinoma is the same as that of the nonpregnant breast carcinoma patient: local control of disease and prevention of systemic metastases. However, certain treatment modalities need to be modified because of the potential for adverse effects on the fetus. There is evidence to support the safety of anthracycline-based chemotherapy during the second and third trimesters of pregnancy (Oxford Level of Evidence [LOE] 2b). Because of the lack of evidence, the expert opinion was not to recommend the routine use of newer cytotoxic drugs like the taxanes during pregnancy (LOE 5). CONCLUSION. The recommendations provided should help to reach informed decision making by the patient. The ongoing prospective collection of data on BCP, such as that at the University of Texas M.D. Anderson Cancer Center (UTMDACC) and that of the German Breast Group/Breast International Group (GBG/BIG), is necessary to further our knowledge regarding the treatment of this unique group of breast carcinoma patients.

AB - BACKGROUND. Breast carcinoma during pregnancy (BCP) is a difficult clinical situation, as it appears to put the health of the mother in conflict with that of the fetus. METHODS. An international expert meeting was conducted to form guidelines on how to diagnose and treat women with BCP. RESULTS. The goal for treatment of the pregnant woman with breast carcinoma is the same as that of the nonpregnant breast carcinoma patient: local control of disease and prevention of systemic metastases. However, certain treatment modalities need to be modified because of the potential for adverse effects on the fetus. There is evidence to support the safety of anthracycline-based chemotherapy during the second and third trimesters of pregnancy (Oxford Level of Evidence [LOE] 2b). Because of the lack of evidence, the expert opinion was not to recommend the routine use of newer cytotoxic drugs like the taxanes during pregnancy (LOE 5). CONCLUSION. The recommendations provided should help to reach informed decision making by the patient. The ongoing prospective collection of data on BCP, such as that at the University of Texas M.D. Anderson Cancer Center (UTMDACC) and that of the German Breast Group/Breast International Group (GBG/BIG), is necessary to further our knowledge regarding the treatment of this unique group of breast carcinoma patients.

KW - Breast carcinoma

KW - Chemotherapy

KW - Pregnancy

KW - Recommendation

UR - http://www.scopus.com/inward/record.url?scp=30744459870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30744459870&partnerID=8YFLogxK

U2 - 10.1002/cncr.21610

DO - 10.1002/cncr.21610

M3 - Article

C2 - 16342247

AN - SCOPUS:30744459870

VL - 106

SP - 237

EP - 246

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -